Primary Care Physicians | Diabetes Educators | Nurse Practitioners | Nurses | Cardiologists | Endocrinologists | Internists | Nephrologists | Pharmacists The PCSK9 Revolution in Saturday, January 31, 2015 | 8:00 a.m. – 3:00 p.m. The Li Ka Shing Knowledge Institute of St. Michael’s Hospital Cholesterol Reduction Allan Waters Family Auditorium, 209 Victoria Street, , ON M5B 1T8

Faculty Chair Co-Chair Steven A. Grover, MD, MPA, FRCPC Professor, Departments of Medicine and Epidemiology & Biostatistics, McGill University Founding Director, Cardiovascular Health Improvement Program, McGill University Founding Director, Centre for the Analysis of Cost-Effective Care, Montreal General Hospital Founding Director, Centre for Cardiovascular Risk Assessment, Montreal General Hospital Senior Physician, Montreal General Hospital, McGill University Health Centre Lawrence A. Leiter, MD, FRCPC, FACP, FAHA Subodh Verma, MD, PhD, FRCSC, FAHA Consulting Physician, Department of Community Director, Lipid Clinic, St. Michael’s Hospital Health, Montreal, Quebec Cardiac Surgeon, St. Michael’s Hospital Professor of Medicine and Nutritional Sciences, Professor of Surgery and Pharmacology, Robert A. Hegele MD, FRCPC, FACP University of Toronto Toronto, Research Chair in Atherosclerosis Jacob J. Wolfe Distinguished Medical Research Chair Edith Schulich Vinet Canada Research Chair (Tier 1) Toronto, Ontario in Human Genetics Agenda Martha Blackburn Chair in Cardiovascular Research Distinguished University Professor of Medicine and 8:00 a.m. Registration and breakfast Biochemistry, University of Western Ontario 9:00 a.m. Welcome and program objectives Dr. Lawrence Leiter (Chair) G. B. John Mancini, MD, FRCPC, FACP, FACC Professor of Medicine; University of British Columbia; Session 1: What is PCSK9 and why is it important? Department of Medicine, Division of Cardiology; Research Director, Division of Cardiology; Director, Cardiovascular Imaging Research Core Laboratory 9:10 a.m. The discovery of PCSK9: A Canadian legacy Dr. Nabil G. Seidah (CIRCL); President, Vancouver Hospital Medical, Dental and Allied Staff; Staff Cardiologist, VH 9:30 a.m. PCSK9 inhibitors: How do they work? Dr. Ruth McPherson Cardiology Clinics and Cardiac Computed Tomographic Angiography Program; Staff Cardiologist, St. Paul’s 9:50 a.m. Genetics of cholesterol and FH: What you must know Dr. Robert Hegele Hospital Healthy Heart/Prevention Clinic 10:10 a.m. Panel discussion / Q&A Ruth McPherson, BSc, MSc, PhD, 10:40 a.m. Refreshment break MD, FRCPC Director, Ruddy Canadian Cardiovascular Session 2: Clinical Translational Studies Genetics Centre Director, Atherogenomics Laboratoryand Lipid Clinic Director of Research, Division of Cardiology 11:10 a.m. Why do we need statin alternatives? Dr. G. B. John Mancini University of Ottawa Heart Institute Professor, Departments of Medicine and Biochemistry 11:30 a.m. PCSK9 inhibitors: Results of recent studies Dr. Lawrence Leiter University of Ottawa 11:50 a.m. Ongoing clinical trials of PCSK9 inhibitors Dr. Jean-Claude Tardif Nabil G. Seidah, C.M., O.Q., PhD, MSRC 12:10 p.m. Panel discussion / Q&A Director, Biochemical Neuroendocrinology research unit Full IRCM Research Professor 12:40 p.m. Lunch Full research professor, Department of Medicine (accreditation in molecular biology and biochemistry), Université de Montréal Session 3: Practical Application Adjunct Professor, Department of Medicine (Division of Experimental Medicine), McGill University 1:30 p.m. Injectable cholesterol lowering therapies: Dr. Shafiq Qaadri Canada Research Chairholder in Precursor Proteolysis 2011 Wilder-Penfield Prix du Québec What are the issues? Member, Order of Canada Officer, Ordre national du Québec 1:50 p.m. Lipid guidelines: Where will PCSK9 Inhibitors likely fit in? Dr. Ruth McPherson Fellow, Royal Society of Canada 2:10 p.m. The pharmacoeconomics of lipid lowering: Dr. Steven Grover Jean-Claude Tardif, MD, FRCPC, What is the bar for a new therapy? FACC, FCAHS Scientific Director, Montreal Heart Institute 2:30 p.m. Panel discussion / Q&A Coordinating Center (MHICC) Full Professor, Faculty of Medicine, 3:00 p.m. Closing and program evaluation Dr. Subodh Verma (Co-Chair) Université de Montréal Canada Research Chair in Translational and Personalized Medicine Pfizer Chair in Atherosclerosis, Université de Montréal Registration fee: $39 (includes HST) Chair, Steering Committee, Canadian Atherosclerosis To register please go to Imaging Network (CAIN) (covers attendance at full day program, meeting materials, President, Medical Imaging Trial Network of Canada (MITNEC) www.eply.com/PCSK9 all meals and refreshments)

Shafiq Qaadri, MD, MPP Family Physician, CME Lecturer, Medical Writer For more information please contact S&L Solutions at 289-232-4229 or [email protected] Toronto, Ontario

This program is supported by GOLD: SILVER: educational grants from: